For peptide receptor targeting usually internalizing agonists are selected. There is increasing evidence that non-internalizing receptor antagonists can be used for this purpose. We investigated whether the glucagon-like peptide-1 receptor (GLP-1R) antagonist exendin(9-39) can be used for in vivo targeting of GLP-1R expressing tumours and compared the in vitro and in vivo characteristics to the GLP-1R agonists exendin-3 and exendin-4. The binding and internalization kinetics of labelled [Lys 40 (DTPA)]exendin-3, [Lys 40 (DTPA)]exendin-4 and [Lys 40 (DTPA)]exendin(9-39) were determined in vitro using INS-1 cells. The in vivo targeting properties of [Lys 40 ( 111 In-DTPA)]exendin-3, [Lys 40 ( 111 In-DTPA)]exendin-4 and [Lys 40 ( 111 In-DTPA)]exendin(9-39) were examined in BALB/c nude mice with subcutaneous INS-1 tumours. nat In-labelled [Lys 40 (DTPA)]exendin-3, [Lys 40 (DTPA)]exendin-4 and [Lys 40 (DTPA)]exendin(9-39) exhibited similar IC 50 values (13.5, 14.4 and 13.4 nM, respectively) and bound to 26 × 10 3 , 41 × 10 3 and 37 × 10 3 receptors/cell, respectively. [Lys 40 ( 111 In-DTPA)]exendin-3 and [Lys 40 ( 111 In-DTPA)]exendin-4 showed rapid in vitro binding and internalization kinetics, whereas [Lys 40 ( 111 In-DTPA)]exendin(9-39) showed lower binding and minimal internalization in vitro. In mice, high specific uptake of [Lys 40 ( 111 In-DTPA)]exendin-3 (25.0 ± 6.0 %ID/g) in the tumour was observed at 0.5 h p.i. with similar uptake up to 4 h p.i.. [Lys 40 ( 111 In-DTPA)]exendin-4 showed higher tumour uptake at 1 and 4 h p.i. (40.8 ± 7.0 and 41.9 ± 7.2 %ID/g, respectively). Remarkably, [Lys 40 ( 111 In-DTPA)]exendin(9-39) showed only low specific uptake in the tumour at 0.5 h p.i. (3.2 ± 0.7 %ID/g), rapidly decreasing over time.
Introduction
Peptide receptor targeting is a successful method for the diagnosis and therapy of neuroendocrine tumours (NET) (1) with somatostatin receptor targeting as the most successful example. In general, agonists are selected for receptor targeting, because agonists usually trigger the internalization of the ligand-receptor complex (2) . Internalization of the ligand-receptor complex is the basis for increasing target-to-background ratios, due to retention of the radiolabelled tracer in the target tissue through metabolic trapping (1, (3) (4) (5) (6) . Therefore, internalization is considered to be a crucial step for in vivo peptide receptor targeting (5, 6) . A correlation between internalization rate and in vivo accumulation of radiolabelled somatostatin analogues in somatostatin receptor subtype 2 (sstr2) has been found in rats with AR42J tumours (7) .
Most peptide receptor antagonist do not internalize, while they do bind to the same receptor with high affinity. Antagonists were considered not be suitable for in vivo imaging of tumours due to the lack of internalization. This has been supported by several studies, for example a study showing that a bombesin agonist displayed superior in vivo targeting characteristics in comparison to the antagonist (8) . However, recent studies showed favourable in vivo targeting of radiolabelled bombesin antagonists with higher tumour uptake and longer washout compared to bombesin agonists (9) (10) (11) . Moreover, a recent study with somatostatin receptor type 2 (sstr 2) and type 3 (sstr 3) ligands showed a remarkably higher uptake in the tumour of the antagonists than the agonists (12) . Therefore, there is increasing evidence that peptide receptor antagonists may be useful for the in vivo targeting of receptor expressing tissues.
Insulinomas are NET derived from pancreatic beta cells. Although somatostatin receptor scintigraphy is highly efficient in detecting NET and their metastases (13) , the sensitivity for the detection of insulinomas is only 40-60% caused by a relatively low incidence of sstr2 and sstr5 receptor subtype expression in insulinomas (13) (14) (15) . In comparison, the glucaconlike peptide-1 receptor (GLP-1R) is expressed on more than 90% of insulinomas and at a mean density that is two times higher than that of the sst2r (16) . Exendin is a GLP-1 (glucagon-like peptide-1) analogue that targets the GLP-1R. For the detection of insulinomas, radiolabelled exendin has been developed recently, with promising preclinical as well as clinical results (17) (18) (19) (20) . Therefore, exendin analogues should be considered for insulinoma targeting (17) (18) (19) (20) (21) .
For the targeting of the GLP-1R, only agonists (exendin-3 and exendin-4) labelled with 111 In via DTPA conjugated to a C-terminal lysine residue have been examined (17, 18, (20) (21) (22) . The GLP-1R antagonist exendin(9-39) is an amino-terminally truncated variant prepared by enzymatic degradation of exendin (Table 1) . We aimed to investigate whether exendin(9-39) may also be suitable or -in analogy to the sstr2, sstr3 and bombesin antagonists (9-12) -may even be superior for insulinoma imaging as compared to exendin 3 and 4. Therefore, we investigated the in vitro and in vivo GLP-1R targeting characteristics of the GLP-1R antagonist exendin(9-39) conjugated with DTPA at a C-terminal Lysine: [Lys 40 (DTPA)]exendin(9-39) and compared these with these of agonists [Lys 40 (DTPA)]exendin-3 and [Lys 40 (DTPA)]exendin-4.
Results

Radiolabelling
All peptides could be labelled with 111 In with a specific activity of up to 700 GBq/μmol. Radiochemical purity was >99% as determined by HPLC and ITLC. 111 In-EDTA eluted from the column after 3 min whereas 111 In-labelled [Lys 40 (DTPA)]exendin-3, [Lys 40 (DTPA)]exendin-4 and [Lys 40 (DTPA)]exendin(9-39) had a retention time of ~13 min.
Receptor binding assays
The results of the IC 50 determination are shown in Figure 1 and The results of the saturation binding assay are summarized in Figure 2 and Table 2 . 
Biodistribution studies
The results of the biodistribution studies are summarized in Figure 4 . [Lys 40 ( 111 In-DTPA)]exendin-3 showed high uptake in the tumour as soon as 30 min after injection (25.0 ± 6.0 %ID/g) and a similar uptake was observed up to 4 h p.i. (26.5 ± 8.9 %ID/g). There was no significant difference in tumour uptake between any time points. Co-administration of an excess unlabelled exendin resulted in much lower uptake: 2.4 ± 0.5 %ID/g, indicating that the uptake was GLP-1R-mediated. Specific uptake of [Lys 40 ( 111 In-DTPA)]exendin-3 was also seen in pancreas, lung and stomach. [Lys 40 ( 111 In-DTPA)]exendin-4 showed a higher tumour uptake: 30.7 ± 6.1 %ID/g at 0.5 h p.i. increasing to 41.9 ± 7.2 %ID/g at 4 h p.i. and was statistically higher than tumour uptake of [Lys 40 ( 111 In-DTPA)]exendin-3 at 1 and 4 h p.i. (p = 0.04 and 0.02, respectively). There was no significant difference in pancreas, stomach and lung uptake between [Lys 40 ( 111 In-DTPA)]exendin-3 and [Lys 40 ( 111 In-DTPA)]exendin-4. In contrast, [Lys 40 ( 111 In-DTPA)]exendin(9-39) showed much lower uptake in the tumour at 0.5 h p.i.: 3.2 ± 0.7 %ID/g and there was a rapid wash-out of [Lys 40 ( 111 In-DTPA)]exendin(9-39) from the tumour. The same phenomenon was found in all GLP-1R positive organs (pancreas, lung, stomach and duodenum).
Renal uptake was significantly higher with [Lys 40 ( 111 In-DTPA)]exendin-3 and [Lys 40 ( 111 In-DTPA)]exendin-4 compared to renal uptake of [Lys 40 ( 111 In-DTPA)]exendin(9-39) (p=0.0003 and p=0.0002 respectively).
Discussion
In this study, the tumour targeting characteristics of the GLP-1 receptor (GLP-1R) antagonist exendin(9-39) and the agonists exendin-3 and exendin-4 were evaluated in vitro and in vivo. We found that [Lys 40 ( nat In-DTPA)]exendin(9-39) had a similar affinity for the GLP-1R as the agonists [Lys 40 ( nat In-DTPA)]exendin-3 and [Lys 40 ( nat In-DTPA)]exendin-4, as determined in the IC 50 assay. [Lys 40 ( 111 In-DTPA)]exendin(9-39) bound to a similar number of receptors per cell in vitro as compared to the 111 In-labelled agonists. The results of the IC 50 determination and the Scatchard analysis of exendin-3 were paradoxal: the IC 50 of exendin-3 (13.5 nM) was significantly higher than the K d as derived from the Scatchard analysis (8.7 nM). This could be due to the fact that in the Scatchard analysis 111 In-labelled exendin-3 was used, while in the IC 50 nonradioactive exendin-3 was used.
Despite the high affinity, [Lys 40 ( 111 In-DTPA)]exendin(9-39) showed lower in vitro binding compared to the agonists and minimal internalization as compared to the agonists. The biodistribution study showed high uptake of the agonists in the tumour and in GLP-1R positive organs (pancreas, lung and stomach). In contrast, [Lys 40 ( 111 In-DTPA)]exendin(9-39) showed much lower uptake in GLP-1R expressing tissues at 0.5 h p.i. and the uptake rapidly decreased at later time points. These results suggest that internalization is a prerequisite for specific accumulation of the ligand in GLP-1R expressing tissues in vitro and in vivo.
Previous studies showed favourable tumour targeting of antagonists compared to agonists, that could be explained by the fact that the antagonists bound to more receptors than the agonists (9, 12, 24, 25) . In our study there was no significant difference between the number of receptors bound by [Lys 40 ( 111 In-DTPA)]exendin(9-39) and agonists [Lys 40 ( 111 In-DTPA)]exendin-3 and [Lys 40 ( 111 In-DTPA)]exendin-4. Our study showed that [Lys 40 ( 111 In-DTPA)]exendin(9-39) is not suitable for the targeting of the GLP-1R in vivo. A recent study evaluated the potency of 125 I-exendin(9-39) for pancreatic beta cell imaging and showed high uptake in the pancreas (approximately 20% ID/g) of ddY mice (26) . A difference between the two studies is the peptide dose injected. We have previously shown that the optimal peptide dose for the GLP-1R agonist [Lys 40 ( 111 In-DTPA)]exendin-3 in BALB/c nude mice with a subcutaneous tumour model is < 0.1μg (27) . The peptide dose of 125 Iexendin(9-39) was 60-fold lower than the peptide dose in our study (0.0017 μg vs. 0.1 μg), which might explain the enhanced pancreatic uptake of 125 I-exendin . A straight comparison between the two tracers is needed to clarify the cause of the paradoxal results in the two studies. Although high pancreatic uptake was observed of 125 I-exendin(9-39), the feasibility for beta-cell imaging remains to be determined, because for imaging purposes higher activity doses and thus higher peptide doses will be required.
By in vitro autoradiography Waser et al. found that 125 I-exendin(9-39) had a high affinity for the GLP-1R in murine pancreatic tissue (2.6 ± 0.4 nM), whereas the affinity for the human GLP-1R is much lower (63 ± 47 nM) (28) . It should be noted that this study does not provide data to show that GLP-1R antagonists are superior or inferior to GLP-1R agonists.
Our biodistribution study showed high uptake for all peptides in the kidney, which was not GLP-1R-mediated. The renal uptake of the radiolabelled tracer is caused by tubular reabsorbtion after glomerular filtration. The renal uptake of [Lys 40 ( 111 In-DTPA)]exendin 
Cell culture
The rat insulinoma cell line INS-1 (29) was maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 μM βmercaptoethanol, 1 mM sodium pyruvate, 100 units/ml penicillin and 100 μg/ml streptomycin, in a humidified 5% CO 2 atmosphere at 37 °C. The cells were harvested by trypsinization with trypsin/EDTA.
Receptor binding assays
The 50% inhibitory concentration ( The cells were incubated on ice, to prevent internalization, for 4 h. After incubation the cells were centrifuged at 3,000 g for 5 min, the supernatant was discarded and the cells were washed with 500 μl ice-cold PBS. The radioactivity in the cell pellet was determined in a counter. The bound fraction (in receptors/cell) was plotted against the tracer concentration added. In the scatchard plot the bound/free was plotted against the bound fraction and the dissociation constant (K d ) and the maximum number of binding sites was calculated by nonlinear regression using GraphPad Prism (version 4).
Internalization assay
The kinetics of internalization of [Lys 40 ( 111 In-DTPA)]exendin-3, [Lys 40 ( 111 In-DTPA)]exendin-4 and [Lys 40 ( 111 In-DTPA)]exendin(9-39) were determined using suspensions of INS-1 cells as described above. Approximately 1,000 Bq of 111 In-labelled peptide (55 fmol) was added and incubated for 0.5, 1, 2 or 4 h at 37 °C. After incubation, the cells were centrifuged and the supernatant was discarded. The cells were washed twice with 0.5 ml ice-cold PBS and subsequently 0.5 ml acid buffer (0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added. After 10 min incubation at 4 °C, cells were spun down and the pellet was washed twice with ice-cold PBS. The radioactivity associated with the cell pellet (internalized fraction) and the supernatants (receptor-bound fraction) was determined.
Biodistribution studies
Animal experiments were performed after approval of the local ethical committee (RUDEC) for animal experiments (RUDEC). Six to eight weeks old female BALB/c nude mice were injected subcutaneously with 0. Amino acid sequence of GLP-1, exendin-3, exendin-4 and exendin 
